Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONCY Oncolytics Biotech Inc

休市中 09-18 16:00:00 EDT

0.7700

+0.0000

0.00%

盘后0.7884

+0.0184+2.39%

19:30 EDT

最高0.7775	最低0.7553	成交量49.19万
今开0.7752	昨收0.7700	日振幅2.88%
总市值9,818万	流通市值9,469万	总股本1.28亿
成交额37.80万	换手率0.40%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.77,"timestamp":1789761600000,"preClose":0.77,"halted":0,"volume":491900,"hourTrading":{"tag":"盘后","latestPrice":0.7884,"preClose":0.77,"latestTime":"19:30 EDT","volume":696,"amount":541.6189,"timestamp":1789774205017,"change":0.0184,"changeRate":0.023896,"amplitude":0.023896},"delay":0,"changeRate":0,"floatShares":122973676,"shares":127510505,"eps":-0.3215,"marketStatus":"休市中","change":0,"latestTime":"09-18 16:00:00 EDT","open":0.7752,"high":0.7775,"low":0.7553,"amount":378043.8422,"amplitude":0.028831,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.3215,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.77,"preHourTrading":{"tag":"盘前","latestPrice":0.77,"preClose":0.77,"latestTime":"09:29 EDT","volume":4667,"amount":3625.4579094499995,"timestamp":1789738199999,"change":0,"changeRate":0,"amplitude":0.028831},"postHourTrading":{"tag":"盘后","latestPrice":0.7884,"preClose":0.77,"latestTime":"19:30 EDT","volume":696,"amount":541.6189,"timestamp":1789774205017,"change":0.0184,"changeRate":0.023896,"amplitude":0.023896},"volumeRatio":0.4852886218919694},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"1140402922","title":"Oncolytics Biotech®宣布：Pelareorep联合Pan-Ras抑制剂在结直肠癌临床前研究中取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1140402922","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140402922?lang=zh_cn&edition=full","pubTime":"2026-09-10 20:15","pubTimestamp":1789042532,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech®今日披露了一项振奋人心的临床前研究数据——其核心候选药物Pelareorep与一种Pan-Ras抑制剂联用，在结直肠癌模型中展现出显著的抗肿瘤活性。这一组合策略的积极结果，为攻克携带Ras突变的难治性结直肠癌提供了新的可能性。该公司指出，该联合疗法不仅在体外实验中有效抑制了肿瘤细胞增殖，更在体内模型中观察到肿瘤体积的明显缩小，且安全性特征良好，未出现意料之外的毒副作用。基于这些令人鼓舞的发现，Oncolytics Biotech表示，将加速推进这一联合方案向临床阶段的转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104490185","title":"Oncolytics Biotech®与FDA就二线Ras突变型MSS结直肠癌注册路径达成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1104490185","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104490185?lang=zh_cn&edition=full","pubTime":"2026-08-18 21:03","pubTimestamp":1787058188,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech®已与美国食品药品监督管理局（FDA）就其用于二线治疗Ras突变型微卫星稳定（MSS）结直肠癌的注册路径达成一致意见。这一进展标志着该公司在推进这一适应症候选药物开发过程中迈出了关键一步。通过与监管机构的积极沟通，公司现已明确后续临床开发及上市申请所需的关键要素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120027141","title":"Oncolytics Biotech® 旗下Pelareorep获二线及以后肛门癌适应症快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120027141","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120027141?lang=zh_cn&edition=full","pubTime":"2026-07-20 21:01","pubTimestamp":1784552476,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech® 宣布，其用于治疗二线及以后肛门癌的药物Pelareorep已获得快速通道资格认定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156217952","title":"Oncolytics Biotech：剩余33个Reo试验中心将于八月底前启动，以加速2026年下半年患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1156217952","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156217952?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:11","pubTimestamp":1783948283,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech宣布，为加速推进2026年下半年的患者招募工作，其剩余的33个Reo试验中心计划于八月底前全部启动。这一举措旨在提升试验效率，加快相关临床研究的整体进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160124056","title":"Oncolytics Biotech®宣布FDA监管里程碑及Ras突变MSS结直肠癌随机试验取得强劲临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1160124056","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160124056?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:11","pubTimestamp":1783948261,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech®宣布，其在针对Ras突变型微卫星稳定（MSS）结直肠癌的随机临床试验中，取得了美国食品药品监督管理局（FDA）的监管里程碑，并展现出强劲的临床进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177348668","title":"Oncolytics Biotech：Reo 33试验A部分肿瘤反应初步更新预计2026年底前公布；B部分招募或于2027年一季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1177348668","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177348668?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:08","pubTimestamp":1783948110,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc宣布，其Reo 33临床试验的A部分初步肿瘤反应数据更新，预计将在2026年年底前获得。与此同时，该试验的B部分患者招募工作，有望于2027年第一季度正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136116202","title":"Oncolytics Biotech：Reo 33临床半数试验点本月启动，超20名患者已预先确定","url":"https://stock-news.laohu8.com/highlight/detail?id=1136116202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136116202?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:02","pubTimestamp":1783947740,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech公司宣布，其Reo 33临床研究项目将迎来关键进展。预计本月内，将有半数临床试验中心完成启动工作。与此同时，超过20名潜在患者已被预先识别，为后续的入组工作做好了充分准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179113225","title":"新闻发布：昂科利生物科技宣布史蒂夫·格洛弗加入董事会，并晋升约翰·麦卡多里为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1179113225","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179113225?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:03","pubTimestamp":1780405430,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年6月2日——临床阶段公司昂科利生物科技股份有限公司今日宣布，任命史蒂夫·格洛弗加入其董事会，并晋升约翰·麦卡多里为首席运营官。该公司致力于开发研究性、系统性活性的免疫疗法pelareorep，该疗法可促进潜在的保护性免疫反应，包括上调关键炎症细胞因子，从而形成三级淋巴结构并扩增肿瘤浸润淋巴细胞。昂科利正积极寻求战略合作伙伴关系，以加速开发并最大化商业影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4588","BK4139","BK4232","R","BK4022","ONCY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191269322","title":"Oncolytics Biotech®宣布任命Steve Glover为董事会成员并晋升John Mcadory为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1191269322","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191269322?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:02","pubTimestamp":1780405332,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech®今日宣布两项重要人事变动。Steve Glover被任命为公司董事会成员，其丰富的行业经验将为公司战略发展提供新的视角与支持。同时，公司内部擢升John Mcadory为首席运营官，他将负责监督日常运营活动，推动公司核心业务的高效执行。这两项任命旨在强化公司治理结构与运营领导力，以支持Oncolytics Biotech Inc未来的发展计划与目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765792","title":"Oncolytics Biotech Inc：KRAS突变MSS型MCRC二线治疗反应持续时间较历史基准提升3-4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765792","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120765792?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:09","pubTimestamp":1777900185,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc最新研究数据显示，针对KRAS突变的微卫星稳定型转移性结直肠癌患者的二线治疗，其治疗反应持续时间取得显著突破。与历史基准的4-6个月相比，当前疗法使患者反应持续时间实现3-4倍的提升。\n这一突破性进展为晚期结直肠癌治疗领域注入新希望。尤其对于携带KRAS突变且微卫星状态稳定的患者群体，传统治疗方案效果有限，新数据预示着靶向治疗策略的重要进展。\n研究结果凸显了Oncolytics Biotech在肿瘤免疫治疗领域的创新实力。该公司专注于开发溶瘤病毒疗法，此次数据进一步验证了其技术平台在难治性癌症治疗中的潜在价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176989151","title":"Oncolytics Biotech Inc - Pelareorep联合疗法在二线KRAS突变MSS型结直肠癌中展现19.5个月中位缓解持续时间","url":"https://stock-news.laohu8.com/highlight/detail?id=1176989151","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176989151?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:08","pubTimestamp":1777900124,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc宣布，其核心候选药物pelareorep联合疗法在针对二线治疗KRAS突变、微卫星稳定（MSS）型转移性结直肠癌（mCRC）的临床试验中取得积极数据。研究结果显示，该联合治疗方案的中位缓解持续时间达到19.5个月，展现出持久的抗肿瘤活性。\n这一数据凸显了pelareorep在难治性结直肠癌患者群体中的治疗潜力，特别是针对KRAS突变这一常见且治疗挑战较大的亚型。较长的缓解持续时间可能为患者带来更显著的临床获益，也为后续临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100043313","title":"Oncolytics Biotech Inc 将开会讨论Pelareorep在二线及后线SCAC中的单臂关键研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1100043313","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100043313?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:02","pubTimestamp":1775480546,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc 宣布将召开会议，重点讨论其候选药物Pelareorep在二线及后线转移性结直肠腺癌（SCAC）患者中进行的单臂关键性研究。该研究旨在评估Pelareorep在这一难治患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177910860","title":"Oncolytics Biotech Inc 定于2026年4月16日就Pelareorep用于肛门癌适应症召开FDA C类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1177910860","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177910860?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:01","pubTimestamp":1775480480,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc (ONCY) 已安排于2026年4月16日与美国食品药品监督管理局（FDA）举行C类会议，会议核心议题将聚焦其候选药物Pelareorep在肛门癌领域的应用前景。此次会议旨在就相关研发路径与监管要求进行深入探讨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518700012","title":"加拿大皇家银行：维持Oncolytics Biotech(ONCY.US)评级，由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518700012","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518700012?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:52","pubTimestamp":1741625543,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Oncolytics Biotech(ONCY.US)评级，由优于大市调整至优于大市评级, 目标价由6.00美元调整至5.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11005248641243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518713012","title":"Oncolytics Biotech Inc.盘中异动 早盘大幅下跌5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518713012","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518713012?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:52","pubTimestamp":1741614720,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时52分，Oncolytics Biotech Inc.股票出现波动，股价快速下挫5.59%。截至发稿，该股报0.650美元/股，成交量2.8965万股，换手率0.04%，振幅5.78%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2809.66%、628.56%、126.92%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021520198a2a262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021520198a2a262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONCWF","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109304519","title":"Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42)，$1590万现金余量可支撑至2025年第三季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1109304519","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109304519?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:12","pubTimestamp":1741349531,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech 报告季度每股亏损$，优于分析师预期的$，超出2.38%。这与去年同期持平。以上内容来自Benzinga Earnings专栏，原文如下：Oncolytics Biotech  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.38 percent. This is unchanged from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech 2024财年GAAP每股收益(C$0.41)优于预期(C$0.42)，$1590万现金余量可支撑至2025年第三季度","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517660251","title":"Oncolytics Biotech Inc.盘中异动 早盘股价大跌5.12%报0.700美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517660251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517660251?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:44","pubTimestamp":1741272275,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时44分，Oncolytics Biotech Inc.股票出现异动，股价大幅跳水5.12%。截至发稿，该股报0.700美元/股，成交量5.4394万股，换手率0.07%，振幅3.48%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1276.82%、263.37%、58.71%，振幅较大的相关个股有Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为31.46%、30.53%、23.72%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224435abeb7b5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306224435abeb7b5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","ONCWF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517940666","title":"Oncolytics Biotech Inc.盘中异动 快速拉升6.03%报0.689美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517940666?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:51","pubTimestamp":1741197100,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时51分，Oncolytics Biotech Inc.股票出现波动，股价急速拉升6.03%。截至发稿，该股报0.689美元/股，成交量5.0539万股，换手率0.07%，振幅4.60%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为1.24%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为942.34%、304.49%、296.39%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306015140989d727e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306015140989d727e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONCY","ONCWF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677970","title":"Oncolytics Biotech Inc.盘中异动 早盘股价大跌6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677970?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:31","pubTimestamp":1741098674,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时31分，Oncolytics Biotech Inc.股票出现波动，股价快速下挫6.49%。截至发稿，该股报0.620美元/股，成交量5.3039万股，换手率0.07%，振幅0.00%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Exicure, Inc.、Protagenic Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1047.69%、1024.96%、405.58%，振幅较大的相关个股有Orchestra Biomed Holdings, Inc.、Hoth Therapeutics, Inc.、Jasper Therapeutics, Inc.，振幅分别为5.85%、5.06%、4.84%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223114a25f03fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223114a25f03fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCWF","ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512806814","title":"Oncolytics Biotech Inc.盘中异动 快速跳水5.18%报0.717美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512806814","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512806814?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:36","pubTimestamp":1739986567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时36分，Oncolytics Biotech Inc.股票出现异动，股价快速下跌5.18%。截至发稿，该股报0.717美元/股，成交量23.1895万股，换手率0.30%，振幅5.29%。Oncolytics Biotech Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Oncolytics Biotech Inc.公司简介：Oncolytics Biotech Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013607988b4f34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013607988b4f34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONCY","ONCWF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0734},{"period":"3month","weight":-0.1979},{"period":"6month","weight":-0.1895},{"period":"1year","weight":-0.4338},{"period":"ytd","weight":-0.119}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Oncolytics Biotech Inc.于1998年4月2日根据亚伯达法律以亚伯达有限责任公司的名字成立，并于2026年4月1日在内华达州重新注册成立。该公司是一家临床阶段的生物制药公司，正在开发pelareorep，这是一种静脉给药的免疫治疗药物，旨在选择性地在RAS突变的肿瘤中复制并激活免疫反应。该公司尚未实现盈利，需要额外融资以维持运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.375,"avgChangeRate":0.014597},{"month":6,"riseRate":0.25,"avgChangeRate":0.155922},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.014421},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.069615},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.031355},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Oncolytics Biotech Inc(ONCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Oncolytics Biotech Inc(ONCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}